NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative ...
Type 1 diabetes, or T1D, results from the autoimmune destruction of the insulin-producing cells of the pancreas. People with T1D require exogenous insulin and suffer swings in the levels of glucose in ...
Encellin, a biotechnology company pioneering Encapsulated Cell Replacement Therapy (ENCRT), today announced interim clinical results from its ongoing Phase 1 investigational trial (NCT06408311) in ...
New York, NY, August 16, 2012 – JDRF, in collaboration with The Leona M. and Harry B. Helmsley Charitable Trust (HCT), announced today that it has finalized a grant in the area of islet cell ...
Patients with Type 1 diabetes are unable to produce enough insulin naturally. One treatment for Type 1 diabetes is pancreatic islet transplantation, in which groups of cells from a donor pancreas are ...
Avant Technologies, Art-Islets, and Austrianova Announce Joint Venture to Advance Diabetes Treatment
LAS VEGAS, Sept. 24, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), a Nevada-based corporation, Art-Islets Pte. Ltd. ("Art ...
Researchers have come up with a novel way to prevent fibrosis, which can lead to rejection of implantable medical devices, by incorporating a crystallized immunosuppressant drug into the devices.
A team of researchers has developed a revolutionary new method for treating type 1 diabetes. Inspired by a spider's web, the team created an easily implantable nanoporous thread that can hold hundreds ...
Type 1 diabetes, or T1D, results from the autoimmune destruction of the insulin-producing cells of the pancreas. People with T1D require exogenous insulin and suffer swings in the levels of glucose in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback